Sumatriptan versus placebo. Calculated NNTs for a pain‐free response after a specified time, in participants treating moderate or severe migraine pain. Results for the five most commonly used dose and route of administration combinations, listed in rank order.

PF2: pain‐free at two hours; PF1: pain‐free at one hour; 24h SPF: 24‐hour sustained pain‐free.

Oral doses are shown with blue bars, subcutaneous doses are shown with red bars, intranasal doses are shown with yellow bars, and rectal doses are shown with green bars.

Sumatriptan versus placebo. Calculated NNTs for headache relief after a specified time, in participants treating moderate or severe migraine pain. Results for the five most commonly used dose and route of administration combinations, listed in rank order.

HR2 (headache relief at two hours); HR1 (headache relief at one hour); 24h SHR (24‐hour sustained headache relief).

Oral doses are shown with blue bars, subcutaneous doses are shown with red bars, intranasal doses are shown with yellow bars, and rectal doses are shown with green bars.

Sumatriptan versus placebo. Calculated NNHs for any adverse event within 24 hours of dosing, in participants treating moderate or severe migraine pain. Results for four of the five most commonly used dose and route of administration combinations (adverse event information for rectal sumatriptan not available), listed in rank order.

Oral doses are shown with blue bars, subcutaneous doses are shown with red bars, and intranasal doses are shown with yellow bars.

Placebo response rates for the primary efficacy outcomes, by route of administration. Response rates of each outcome are grouped by colour to facilitate comparison between different routes of administration. Proportion of placebo‐treated participants pain‐free at two hours are shown with blue bars, pain‐free at one hour with purple bars, 24‐h sustained pain‐free with green bars, headache relief at two hours with red bars, headache relief at one hour with yellow bars, and 24‐h sustained headache relief with a pink bar.

Sumatriptan versus placebo. Calculated NNTs for relief of migraine‐associated symptoms and functional disability after two hours, in participants treating moderate or severe migraine pain. Results for the five most commonly used dose and route of administration combinations, listed in rank order.

Oral doses are shown with blue bars, subcutaneous doses are shown with red bars, intranasal doses are shown with yellow bars, and rectal doses are shown with green bars.